309 reports of this reaction
3.8% of all FINGOLIMOD HYDROCHLORIDE reports
#3 most reported adverse reaction
MULTIPLE SCLEROSIS is the #3 most commonly reported adverse reaction for FINGOLIMOD HYDROCHLORIDE, manufactured by Ascend Laboratories, LLC. There are 309 FDA adverse event reports linking FINGOLIMOD HYDROCHLORIDE to MULTIPLE SCLEROSIS. This represents approximately 3.8% of all 8,208 adverse event reports for this drug.
Patients taking FINGOLIMOD HYDROCHLORIDE who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is moderately reported among FINGOLIMOD HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis, the following adverse reactions have been reported for FINGOLIMOD HYDROCHLORIDE:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 309 FDA reports for FINGOLIMOD HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 3.8% of all adverse event reports for FINGOLIMOD HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience multiple sclerosis while taking FINGOLIMOD HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.